Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) PI3Kδ activation, IL6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Blood Advances, 7 ottobre 2024

2) A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers
haematologica, 20 giugno 2024

3) IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica, 22 febbraio 2024

4) The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
British Journal of Haematology, 27 novembre 2023

5) PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
bioRxiv, 16 novembre 2023

6) ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells
British Journal of Haematology, 16 agosto 2023

7) Marginal zone lymphomas
Hematological Oncology, giugno 2023

8) Myc controls NK cell development, IL-15-driven expansion, and translational machinery
Life Science Alliance, 27 aprile 2023

9) Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog
Veterinary and Comparative Oncology, dicembre 2020

10) Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Cancer Treatment Reviews, novembre 2020

11) The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
Exploration of Targeted Anti-tumor Therapy, 2021

12) MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients
British Society for Haematology, novembre 2021

13) KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells
Oncology Reports, gennaio 2022

14) An epigenetic signature in CD19-CAR T cells predicts clinical outcome
Trends in Cancer, febbraio 2022

15) The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications
Lab Animal, luglio 2022

16) United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
British Journal of Haematology, ottobre 2022

17) A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virus
Biosensors and Bioelectronics: X, maggio 2023

18) Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Exploration of Targeted Anti-tumor Therapy, 2022

19) STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma
Hematological Oncology, febbraio 2020

20) KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Haematologica, giugno 2020

21) Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified
Modern Pathology, febbraio 2020

22) Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
European Journal of Medicinal Chemistry, 15 febbraio 2023

23) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Cell Reports, 28 aprile 2015

24) RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo
European Journal of Medicinal Chemistry, 15 gennaio 2023

25) Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
Journal of Clinical Medicine, 4 gennaio 2023

26) ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
bioRxiv, 2 gennaio 2023

27) Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling
Molecular Cancer, 12 dicembre 2022

28) In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103
British Journal of Haematology, 9 dicembre 2022

29) Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
European Journal of Medical Chemistry, 5 dicembre 2022

30) Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α-STAT3 Axis
Cancer Immunology Research, 2 dicembre 2022

31) HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols
GIGAbyte, 2 dicembre 2022

32) Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Haematologica, 1 novembre 2022

33) A systematic review of contemporary phase I trials in patients with lymphoma
Critical Reviews in Oncology / Hematology, 17 ottobre 2022

34) Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Clinical Cancer Research, 14 ottobre 2022

35) Subcapsular sinus macrophages promote melanoma metastasis to the sentinel lymph nodes via an IL-1α-STAT3 axis
Cancer Immunology Research, 7 ottobre 2022

36) Bacterial infection-driven lymphomagenesis
Current Opinion in Oncology, 1 settembre 2022

37) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
eJHaem, 27 luglio 2022

38) Editorial: New insights into the mechanisms of resistance to anti-cancer drugs
Frontiers in Oncology, 26 luglio 2022

39) Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
Frontiers in Oncology, 13 luglio 2022

40) SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Blood Advances, 12 luglio 2022

41) Marginal-Zone Lymphomas. Reply
The New England Journal of Medicine, 19 maggio 2022

42) Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
Haematologica, 1 maggio 2022

43) Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades
Cancers, 14 aprile 2022

44) A novel phage display based platform for exosome diversity characterization
Nanoscale, 24 febbraio 2022

45) Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood, 3 febbraio 2022

46) Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Scientific Reports, 2 febbraio 2022

47) ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma
Journal of Experimental & Clinical Cancer Research, 11 novembre 2021

48) PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Cancers, 4 novembre 2021

49) A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas
Leukemia & Lymphoma, 19 agosto 2021

50) RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis
BMC Informatics, 3 giugno 2021

51) Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors
Blood Advances, 25 maggio 2021

52) Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Trends in Cancer, 21 maggio 2021

53) HMGA1 induces EZH2 overexpression in human B-cell lymphomas
American Journal of Cancer Research, 15 maggio 2021

54) Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma
Oncogene, 6 maggio 2021

55) Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
Non-coding RNA, 16 aprile 2021

56) Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma
Frontiers in Veterinary Science, 17 marzo 2021

57) Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Nature Communications, 2 febbraio 2021

58) Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Drug Resistance Updates, 16 gennaio 2021

59) Data describing the effects of potassium channels modulators on outward currents measured in human lymphoma cell lines
Data in Brief, 21 dicembre 2020

60) Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Marine Drugs, 4 dicembre 2020

61) DNA Copy Number Changes in Diffuse Large B Cell Lymphomas
Frontiers in Oncology, 2 dicembre 2020

62) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Haematologica, 1 novembre 2020

63) Pyrrolo[2’,3’:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
Journal of Medicinal Chemistry, 22 ottobre 2020

64) Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
Annals of Lymphoma, 30 settembre 2020

65) Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Blood Advances, https://ashpublications.org/bloodadvances/article/4/17/4124/463605/Antitumor-activity-of-the-dual-BET-and-CBP-EP300

66) Targeting BET bromodomain proteins in cancer: The example of lymphomas
Pharmacology & Therapeutics, https://www.sciencedirect.com/science/article/abs/pii/S0163725820301613?via%3Dihub

67) Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
Cancers, 15 luglio 2020

68) Understanding the mechanism of action of pyrrolo[3,2- b]quinoxaline-derivatives as kinase inhibitors
RSC Medical Chemistry, 19 maggio 2020

69) HMGA1-pseudogene7 transgenic mice develop B cell lymphomas
Scientific Reports, 27 aprile 2020

70) An overview on anti-tubulin agents for the treatment of lymphoma patients.
Pharmacology and Therapeutics, https://www.sciencedirect.com/science/article/abs/pii/S0163725820300802?via%3Dihub

71) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
American Society of Hematology, https://ashpublications.org/bloodadvances/article/4/5/819/452604/Copanlisib-synergizes-with-conventional-and

72) Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
International Journal of Molecular Sciences, 5 febbraio 2020

73) Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer
American Journal of Cancer Research, 1 febbraio 2020

74) Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Haematologica, 31 gennaio 2020
Francesco Bertoni
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Lymphoma Genomics
as Group Leader [Rif. 55110]
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently Research Program Leader [Rif. 50110] for
Lymphoma and Genomics (Rif. 20000 2023)